Compile Data Set for Download or QSAR
Report error Found 202 Enz. Inhib. hit(s) with all data for entry = 2740
TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283374(US10023557, Example 26 | N-((6-amino-5-cyano-2-met...)
Affinity DataIC50: 26nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283371(US10023557, Example 23 | N-((6-amino-2,4-dimethylp...)
Affinity DataIC50: 26nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283376(US10023557, Example 28 | N-((6-amino-5-chloro-2-me...)
Affinity DataIC50: 26nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283380(2-((3-chloroquinolin-6-yl)methyl)-N-((6-fluoro- 1H...)
Affinity DataIC50: 26nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283395(US10023557, Example 47 | N-((3-aminobenzo[d]isoxaz...)
Affinity DataIC50: 26nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283384(US10023557, Example 36 | N-((3-aminobenzo[d]isoxaz...)
Affinity DataIC50: 26nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283389(US10023557, Example 259 | 2-((3-chloroquinolin-6-y...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283388(US10023557, Example 40 | N-((3-chloro-4-fluoro-1H-...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283382(US10023557, Example 34 | N-((6-amino-2-methylpyrid...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283394(US10023557, Example 46 | N-((6-amino-2,4-dimethylp...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283382(US10023557, Example 34 | N-((6-amino-2-methylpyrid...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283381(US10023557, Example 33 | N-((3-chloro-6-fluoro-1H-...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283379(N-((1-aminoisoquinolin-6-yl)methyl)-2-((3- chloroq...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283386(US10023557, Example 38 | N-((3-chloro-1H-pyrrolo[2...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283385(US10023557, Example 37 | N-((5-chloro-1H-indazol-3...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283383(US10023557, Example 35 | N-((6-amino-2,4-dimethylp...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283406(US10023557, Example 58 | 6-((4-(((6-amino-2,4-dime...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283405(US10023557, Example 57 | N-((1-aminoisoquinolin-6-...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283404(US10023557, Example 56 | N-((6-amino-2-methylpyrid...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283403(US10023557, Example 55 | N-((3-chloro-1H-pyrrolo[2...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283410(US10023557, Example 62 | 6-((4-(((6-amino-2-methyl...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283409(US10023557, Example 61 | 3-chloro-6-((4-(((3-chlor...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283408(US10023557, Example 60 | 3-chloro-6-((4-(((5-chlor...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283407(US10023557, Example 59 | 3-chloro-6-((4-(((3-chlor...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283398(US10023557, Example 50 | N-((6-amino-2,4-dimethylp...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM377920(US10266515, Example 49 | N-((3-chloro-6-fluoro-1H-...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283402(US10023557, Example 54 | N-((5-chloro-1H-indazol-3...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283400(US10023557, Example 52 | 2-((3-chloro-8-cyanoquino...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283399(US10023557, Example 51 | N-((3-chloro-4-fluoro-1H-...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283422(US10023557, Example 74 | N-((3-chloro-4-fluoro-1H-...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283421(US10023557, Example 73 | N-((3-chloro-1H-pyrrolo[2...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM377943(US10266515, Example 72 | N-((3-chloro-6-fluoro-1H-...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283419(US10023557, Example 71 | N-((1-aminoisoquinolin-6-...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283426(US10023557, Example 78 | 6-((4-(((3-chloro-6-fluor...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283425(US10023557, Example 77 | 6-((4-(((6-amino-2,4-dime...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283424(US10023557, Example 76 | 2-((8-cyano-3-methylquino...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283423(US10023557, Example 75 | N-((5-chloro-1H-indazol-3...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283414(US10023557, Example 66 | 3-chloro-6-((4-(((6-fluor...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283413(US10023557, Example 65 | 3-chloro-6-((4-(((3-chlor...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283412(US10023557, Example 64 | 6-((4-(((1-aminoisoquinol...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283411(US10023557, Example 63 | 6-((4-(((6-amino-4-methyl...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283418(US10023557, Example 70 | N-((6-amino-2,4-dimethylp...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283417(US10023557, Example 69 | N-((6-amino-2-methylpyrid...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283416(US10023557, Example 68 | N-((3-chloro-6-fluoro-1H-...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283415(US10023557, Example 67 | N-((6-amino-2,4-dimethylp...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283438(US10023557, Example 90 | N-((3-chloro-6-fluoro-1H-...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283437(US10023557, Example 89 | N-((6-amino-2,4-dimethylp...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283442(US10023557, Example 94 | N-((6-amino-2,4-dimethylp...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283441(US10023557, Example 93 | 6-((4-(((6-amino-2,4-dime...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283440(US10023557, Example 92 | methyl 6-((4-(((6-amino-2...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
US Patent

Displayed 1 to 50 (of 202 total ) | Next | Last >>
Jump to: